BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 16215709)

  • 1. [The role of PSA in diagnosis of prostate cancer and its recurrence].
    Vergho DC; Heine K; Wolff JM
    Pathologe; 2005 Nov; 26(6):473-8. PubMed ID: 16215709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases.
    Partin AW; Pearson JD; Landis PK; Carter HB; Pound CR; Clemens JQ; Epstein JI; Walsh PC
    Urology; 1994 May; 43(5):649-59. PubMed ID: 7513108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
    Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum.
    Steuber T; Vickers AJ; Haese A; Becker C; Pettersson K; Chun FK; Kattan MW; Eastham JA; Scardino PT; Huland H; Lilja H
    Int J Cancer; 2006 Mar; 118(5):1234-40. PubMed ID: 16152616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Status of PSA determination for early detection of prostate carcinoma].
    Hammerer P; Huland H
    Versicherungsmedizin; 1995 Jun; 47(3):83-6. PubMed ID: 7541925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Digital rectal examination is no longer necessary in the routine follow-up of men with undetectable prostate specific antigen after radical prostatectomy: the implications for follow-up.
    Chaplin BJ; Wildhagen MF; Schroder FH; Kirkels WJ; Bangma CH
    Eur Urol; 2005 Dec; 48(6):906-10. PubMed ID: 16126322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
    Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
    J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New challenges and earlier approved methods in the laboratory diagnosis of prostate cancer].
    Kovács GL
    Magy Onkol; 2014 Dec; 58(4):301-9. PubMed ID: 25517448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group.
    Teeter AE; Bañez LL; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ;
    J Urol; 2008 Nov; 180(5):1980-4; discussion 1985. PubMed ID: 18801519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy.
    Ward JF; Blute ML; Slezak J; Bergstralh EJ; Zincke H
    J Urol; 2003 Nov; 170(5):1872-6. PubMed ID: 14532796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy.
    Bastian PJ; Palapattu GS; Yegnasubramanian S; Lin X; Rogers CG; Mangold LA; Trock B; Eisenberger M; Partin AW; Nelson WG
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5361-7. PubMed ID: 17875764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
    Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
    BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Digital rectal examination and imaging studies are unnecessary in men with undetectable prostate specific antigen following radical prostatectomy.
    Pound CR; Christens-Barry OW; Gurganus RT; Partin AW; Walsh PC
    J Urol; 1999 Oct; 162(4):1337-40. PubMed ID: 10492192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate specific antigen only progression of prostate cancer.
    Moul JW
    J Urol; 2000 Jun; 163(6):1632-42. PubMed ID: 10799151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wisteria floribunda Agglutinin and Its Reactive-Glycan-Carrying Prostate-Specific Antigen as a Novel Diagnostic and Prognostic Marker of Prostate Cancer.
    Hagiwara K; Tobisawa Y; Kaya T; Kaneko T; Hatakeyama S; Mori K; Hashimoto Y; Koie T; Suda Y; Ohyama C; Yoneyama T
    Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28134773
    [No Abstract]   [Full Text] [Related]  

  • 16. Stratification of patient risk based on prostate-specific antigen doubling time after radical retropubic prostatectomy.
    Tollefson MK; Slezak JM; Leibovich BC; Zincke H; Blute ML
    Mayo Clin Proc; 2007 Apr; 82(4):422-7. PubMed ID: 17418069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy.
    D'Amico AV; Chen MH; Roehl KA; Catalona WJ
    N Engl J Med; 2004 Jul; 351(2):125-35. PubMed ID: 15247353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Change in PSA velocity is a predictor of overall survival in men with biochemically-recurrent prostate cancer treated with nonhormonal agents: combined analysis of four phase-2 trials.
    Suzman DL; Zhou XC; Zahurak ML; Lin J; Antonarakis ES
    Prostate Cancer Prostatic Dis; 2015 Mar; 18(1):49-55. PubMed ID: 25384338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [PSA recurrence after primary curative therapy--local or systemic? When is a second curative therapy still possible?].
    Wirth MP; Engelhardt FM
    Urologe A; 2005 Sep; 44(9):997-1004, 1006-7. PubMed ID: 16133232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.